Table 1.
Demographic characteristics of study participants (intent-to-treat and per-protocol analyses)
| Variable | Experimental group | Control group | Active users | Nonactive users |
|---|---|---|---|---|
| Participants, n | 57 | 23 | 18 | 39 |
| Female sex, % | 59.6 | 47.8 | 77.8 | 51.3 |
| Age, years | 33.44 (14.15) | 39.91 (16.06) | 37.2 (13.49) | 31.69 (14.27) |
| Baseline HbA1c, % | 7.41 (1.18) | 7.68 (1.29) | 7.11 (1.61) | 7.55 (0.90) |
| Time since T1D diagnosis, years | 15.85 (12.58) | 15.26 (13.00) | 14.32 (11.83) | 16.56 (13.00) |
| Caucasian, % | 77 | 91 | 66.6 | 82.0 |
| BMI, kg/m2 | 27.42 (5.77) | 26.91 (6.85) | 29.34 (7.39) | 26.53 (4.71) |
| TDI, units/kg | 0.71 (0.26) | 0.72 (0.30) | 0.66 (0.24) | 0.73 (0.27) |
| CGM naïve, % | 47 | 52 | 55.6 | 43.6 |
| Current CGM users, % | 38.6 | 30.4 | 38.9 | 38.5 |
| Basal insulin, % of total daily insulin | 48.7 | 47.3 | 50.9 | 47.6 |
| Participants splitting basal insulin in two injections, % | 22.9 | 34.8 | 22.2 | 23.1 |
Data are presented as mean (SD) unless otherwise indicated.
TDI, total daily insulin.